Profile of the combination of two oral anti-diabetes drugs in patients diabetes melitus at Citra Husada hospital Jember
Keywords:
Diabetes Mellitus, Oral anti-diabetes Drugs, AntidiabeticAbstract
Diabetes melitus (DM) is a group of diseases with characteristic hyperglycemia that occurs due to impaired insulin secretion, insulin action, or both. The International Diabetes Federation (IDF) notes that Indonesia has the country with the fifth most significant number of diabetics in the world, with 19.5 million Indonesians aged 20-79 years suffering from the disease. Therefore this study aims to determine the profile of the use of a combination of two classes of oral hypoglycemic drugs in type 2 DM patients at Citra Husada Hospital in 2022. This research is a descriptive study with retrospective data collection. The population in this study were all outpatients diagnosed with Type 2 DM at Citra Husada Hospital in 2022. Source of medical record data. The number of samples using a population of 100 patients in the outpatient installation at Citra Husada Hospital. This study used a total sampling technique which is a sampling technique that uses all members of the population. Data analysis used univariate analysis in the form of proportions. Research results show that 100 samples are included in the inclusion criteria. Results of the study Most of the patient characteristics were female (61%), age range 56-65 years (39%), and hypertension co-morbidities (33%). The results of a combination study of two classes of oral anti-diabetes drugs, namely the sulfonylurea group (glimepiride at a dose of 3 mg, the drug frequency is taken once a day every morning with the thiazolidinedione group (pioglitazone at a dose of 30 mg, the drug frequency is taken once a day during the day) (35%). The most common used of combinations of two classes of oral anti-diabetes drugs in patients Diabetes melitus at Citra Husada Hospital are sulfonylureas and thiazolidinediones
References
World Health Organization, Diabetes Mellitus. 2021.
D. Almasdy, “Evaluasi Penggunaan Obat Antidiabetik Pada Pasien Diabetes Mellitus Tipe 2 Di Suatu Rumah Sakit Pemerintah Kota Padang- Sumatera Barat,” in Seminar Nasional & Workshop “Perkembangan Terkini Sains Farmasi & Klinik 5,” 2015.
Dinkes Kabupaten Jember, Data Diabetes Melitus. Jember: Dinkes Kabupaten Jember, 2020.
PERKENI, Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021. PERKENI, 2021.
Balkhi, M. Alwhaibi, and N. Algahtani, “Oral Antidiabetic Medicationaadherence And Glycaemic Control Among Patients With Type 2 Diabetesmellitus: A Cross-Sectional Retrospective Study In A Tertiary Hospital In Saudi Arabia,” 2019.
American Diabetes Association, Standar Of Medical Are In Diabetes 2019, vol. 42. USA: American Diabetes Association, 2019.
M. Al Amin and D. Juniati, “Klasifikasi Kelompok Umur Manusia Berdasarkan Analisis Dimensi Fraktal Box Counting Dari Citra Wajah Dengan Deteksi Tepi Canny,” MATHunesa, vol. 2, no. 6, p. 34, 2017, [Online].
R. Arania, T. Triwahyuni, F. Esfandiari, and F. rama Nugraha, “Hubungan antara usia, jenis kelamin, dan tingkat pendidikan dengan kejadian diabetes mellitus di klinik mardi waluyo lampung tengah resti,” J. Med. Malahayati, vol. 5, no. September, pp. 146–153, 2021,
S. Afrilla and S. Hrp, “Pengobatan Pasien Diabetes Program Studi Keperawatan Program Sarjana,” 2019.
Komariah and S. Rahayu, “Dengan Kadar Gula Darah Puasa Pada Pasien Diabetes Melitus Tipe 2 Di Klinik Pratama Rawat Jalan,” J. Kesehat. Kusuma Husada, vol. 11, no. 1, pp. 41–50, 2020, [Online]. [11] S. I. Imelda, “Faktor-Faktor Yang Mempengaruhi Terjadinya diabetes Melitus di Puskesmas Harapan Raya Tahun 2018,” Sci. J., vol. 8, no. 1, pp. 28–39, 2019,
R. N. Fatimah, “Diabetes Melitus Tipe 2,” J Major., vol. 4, no. 5, pp. 93–99, 2015.
O. A. O. Abdelrazig, “Perbandingan Efektivitas Penggunaan Obat Antidiabetik Tunggal Dan Kombinasi Pada Pasien Diabetes Mellitus Tipe Ii Di Rumah Sakit Nasional Al Amal Sudan,” Skripsi, 2021.
M. Hanefeld, “Pioglitazone and sulfonylureas: Effectively treating type 2 diabetes,” Int. J. Clin. Pract., vol. 61, no. SUPPL. 153, pp. 20–27, 2017, doi: 10.1111/j.1742-1241.2007.01361.x.
R. J. Maclsaac, “Clinical indications of thiazolidinediones,” Aust. Prescr., vol. 27, no. 3, pp. 70-74+79, 2018.
N. Mas Ulfa and N. Arfiana, “Efektivitas Penggunaan Oral Antidiabetes Kombinasi Glimepiride Dengan Pioglitazone Pada Pasien Dibetes Mellitus Tipe 2,” J. Pharm. Sci., vol. 5, no. 1, pp. 1–6, 2020, doi: 10.53342/pharmasci.v5i1.154.
J. T. DiPiro, G. C. Yee, L. M. Posey, S. T. Haines, T. D. Nolin, and V. Ellingrod, Pharmacotherapy: A Pathophysiologic Approach, Eleventh E. McGraw Hill, 2020.
PERKI, “Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021,” Glob. Initiat. Asthma, p. 46, 2021, [Online].
D. Z. Fickri, “Journal of Pharmaceutical Care Anwar Medika Artikel Penelitian,” J. Pharm. Care Anwar Med., vol. 1, no. 1, pp. 16–24, 2019.
